{"disease":{"id":"non-metastatic-prostate-cancer","name":"non metastatic prostate cancer"},"drugs":{"marketed":[{"drug_id":"darolutamide","indication_name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nubeqa","generic_name":"darolutamide","company_name":"Bayer","drug_phase":"marketed","molecular_target":"androgen receptor (AR)","drug_class":"","quality_score":76,"revenue":"1600","mechanism":"Darolutamide inhibits androgen receptor activity, reducing prostate cancer cell growth and tumor size."},{"drug_id":"chembl-chembl3183409","indication_name":"Non-metastatic castration-resistant prostate cancer","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"APALUTAMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Androgen Receptor (AR)","drug_class":"","quality_score":48,"revenue":null,"mechanism":"Apalutamide binds to the androgen receptor, blocking its function and reducing tumor growth."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06835218","title":"PROCARE - PROstate Cancer Real World Evidence Registry","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"UroTrials Company (GmbH)","has_results":false},{"nct_id":"NCT06204302","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1800,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02003924","title":"Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1401,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06013475","title":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":1375,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05362149","title":"An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings","phase":"","overall_status":"COMPLETED","enrollment_count":870,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT06334120","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05107674","title":"A Study of NX-1607 in Adults With Advanced Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":345,"lead_sponsor_name":"Nurix Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04925284","title":"Study of XB002 in Subjects With Solid Tumors (JEWEL-101)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":269,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06784193","title":"Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":180,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04400656","title":"PROState Pathway Embedded Comparative Trial","phase":"","overall_status":"COMPLETED","enrollment_count":139,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT03549000","title":"A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":127,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03454451","title":"CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":117,"lead_sponsor_name":"Corvus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04049747","title":"Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT07410494","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":85,"lead_sponsor_name":"Essen Biotech","has_results":false},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT03493945","title":"Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":59,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05348876","title":"A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06555796","title":"Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Amgen","has_results":false},{"nct_id":"NCT04666129","title":"Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Sumitomo Pharma America, Inc.","has_results":false},{"nct_id":"NCT02256111","title":"EXTEND Exercise Trial","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Duke University","has_results":true},{"nct_id":"NCT06982222","title":"Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04318028","title":"An Investigational Scan (7 Tesla MRI) in Diagnosing Cognitive Impairment in Patients With Non-Metastatic Prostate Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05617885","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Praful Ravi, MB BCHir, MRCP","has_results":false},{"nct_id":"NCT03811652","title":"A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT04514484","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03878524","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}